When the opportunity arose for Mark Molloy to return to his native Australia as a group leader at the Australian Proteomics Analysis Facility, he didn’t need a lot of convincing. “I’m an Australian by birth and at heart, and there’s not a lot of opportunities to come back to this country [as a senior level scientist],” he says. Of course, the downside was that he had to give up his position at Pfizer’s Ann Arbor, Mich., research facility working under well-known proteomics researcher Ruth Van Bogelen.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.